The fully linked HTML version of this article has now been published.
Development ePress online publication date 10 May 2006
doi: 10.1242/dev.02383
Research article
Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression
Yong Zhan,
Akihiro Fujino,
David T. MacLaughlin,
Thomas F. Manganaro,
Paul P. Szotek,
Nelson A. Arango,
Jose Teixeira,
and
Patricia K. Donahoe*
* Author for correspondence (e-mail: donahoe.patricia{at}mgh.harvard.edu)
Examination of Müllerian inhibiting substance (MIS) signaling in the rat in vivo and in vitro revealed novel developmental stage- and tissue-specific events that contributed to a window of MIS responsiveness in Müllerian duct regression. The MIS type II receptor (MISRII)-expressing cells are initially present in the coelomic epithelium of both male and female urogenital ridges, and then migrate into the mesenchyme surrounding the male Müllerian duct under the influence of MIS. Expression of the genes encoding MIS type I receptors, Alk2 and Alk3, is also spatiotemporally controlled; Alk2 expression appears earlier and increases predominantly in the coelomic epithelium, whereas Alk3 expression appears later and is restricted to the mesenchyme, suggesting sequential roles in Müllerian duct regression. MIS induces expression of Alk2, Alk3 and Smad8, but downregulates Smad5 in the urogenital ridge. Alk2-specific small interfering RNA (siRNA) blocks both the transition of MISRII expression from the coelomic epithelium to the mesenchyme and Müllerian duct regression in organ culture. Müllerian duct regression can also be inhibited or accelerated by siRNA targeting Smad8 and Smad5, respectively. Thus, the early action of MIS is to initiate an epithelial-to-mesenchymal transition of MISRII-expressing cells and to specify the components of the receptor/SMAD signaling pathway by differentially regulating their expression.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Rajagopal, L. K. Dattilo, V. Kaartinen, C.-X. Deng, L. Umans, A. Zwijsen, A. B. Roberts, E. P. Bottinger, and D. C. Beebe
Functions of the Type 1 BMP Receptor Acvr1 (Alk2) in Lens Development: Cell Proliferation, Terminal Differentiation, and Survival
Invest. Ophthalmol. Vis. Sci.,
November 1, 2008;
49(11):
4953 - 4960.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. P. Szotek, H. L. Chang, K. Brennand, A. Fujino, R. Pieretti-Vanmarcke, C. Lo Celso, D. Dombkowski, F. Preffer, K. S. Cohen, J. Teixeira, et al.
Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics
PNAS,
August 26, 2008;
105(34):
12469 - 12473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G.D. Orvis, S.P. Jamin, K.M. Kwan, Y. Mishina, V.M. Kaartinen, S. Huang, A.B. Roberts, L. Umans, D. Huylebroeck, A. Zwijsen, et al.
Functional Redundancy of TGF-beta Family Type I Receptors and Receptor-Smads in Mediating Anti-Mullerian Hormone-Induced Mullerian Duct Regression in the Mouse
Biol Reprod,
June 1, 2008;
78(6):
994 - 1001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Pangas, X. Li, L. Umans, A. Zwijsen, D. Huylebroeck, C. Gutierrez, D. Wang, J. F. Martin, S. P. Jamin, R. R. Behringer, et al.
Conditional Deletion of Smad1 and Smad5 in Somatic Cells of Male and Female Gonads Leads to Metastatic Tumor Development in Mice
Mol. Cell. Biol.,
January 1, 2008;
28(1):
248 - 257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Renlund, R. Pieretti-Vanmarcke, F. H. O'Neill, L. Zhang, P. K. Donahoe, and J. Teixeira
c-Jun N-terminal Kinase Inhibitor II (SP600125) Activates Mullerian Inhibiting Substance Type II Receptor-Mediated Signal Transduction
Endocrinology,
January 1, 2008;
149(1):
108 - 115.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Klattig, R. Sierig, D. Kruspe, B. Besenbeck, and C. Englert
Wilms' Tumor Protein Wt1 Is an Activator of the Anti-Mullerian Hormone Receptor Gene Amhr2
Mol. Cell. Biol.,
June 15, 2007;
27(12):
4355 - 4364.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Pieretti-Vanmarcke, P. K. Donahoe, L. A. Pearsall, D. M. Dinulescu, D. C. Connolly, E. F. Halpern, M. V. Seiden, and D. T. MacLaughlin
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer
PNAS,
November 14, 2006;
103(46):
17426 - 17431.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. P. Szotek, R. Pieretti-Vanmarcke, P. T. Masiakos, D. M. Dinulescu, D. Connolly, R. Foster, D. Dombkowski, F. Preffer, D. T. MacLaughlin, and P. K. Donahoe
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
PNAS,
July 25, 2006;
103(30):
11154 - 11159.
[Abstract]
[Full Text]
[PDF]
|
 |
|
© The Company of Biologists Ltd 2006